BBR may reduce cholesterol synthesis and alleviate non-alcoholic hepatic steatosis by downregulating the SIRT1-forkhead box O (FOXO)1-SREBP2 signaling pathway in HepG2 cells. This evidence concerns the gene SIRT1 and fatty liver disease.